Scoop: A Penn Parkinson's spinout goes dark as ex-FDA commish Hahn jumps off board
Not even a former FDA commissioner could keep this small biotech alive. Neurology-focused Blackfynn, a 2015 Penn spinout, has gone dark, Endpoints News has learned.
The biotech seemed to hold enough promise for former FDA commissioner Stephen Hahn to sign on to its board as his first move after leaving the agency in January 2021. He joined the board in February 2021 but has since left, a representative for Hahn confirmed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.